ASH 2023 | Rituximab ± lenalidomide as maintenance therapy in elderly patients with R/R FL
Umberto Vitolo, MD, Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy, presents the findings of the final analysis of the Phase III RENOIR trial (NCT02390869) conducted by the Fondazione Italiana Linfomi (FIL), which compared a maintenance therapy of rituximab to rituximab plus lenalidomide following a brief course of chemoimmunotherapy in elderly patients with relapsed/refractory (R/R) follicular lymphoma (FL). Although a greater clinical benefit was observed with the rituximab plus lenalidomide combination, the primary endpoint of two-year progression-free survival (PFS) was not met, and the clinical benefit was lower than expected. Dr Vitolo highlights that this is likely due to the high rate of therapy discontinuation with the combination as a result of adverse events (AEs). This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Lecture Fees: Servier, Roche, Janssen, Incyte, AbbVie; Membership on an entity’s Board of Directors or advisory committees: Novartis, Gilead, Genmab, Bayer.
